登录 注册 会员服务 联系我们

Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells

  • Published:2019-11 Issue: Volume:863 Page:172705
  • ISSN:0014-2999
  • Container-title:European Journal of Pharmacology
  • language:en
  • Short-container-title:European Journal of Pharmacology

Author:

Hamzehlou Sepideh,Momeny Majid,Zandi Zahra,Kashani Bahareh,Yousefi Hassan,Dehpour Ahmad R.,Tavakkoly-Bazzaz Javad,Ghaffari Seyed H.

Funder

Tehran University of Medical Sciences, Tehran, Iran

Publisher

Elsevier BV

Subject

Pharmacology

Reference111 articles.

1. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction;Adelstein;Investig. New Drugs,2012

2. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology;Ajani;Jpn. J. Clin. Oncol.,2016

3. Gastric adenocarcinoma;Ajani;Nat. Rev. Dis. Prim.,2017

4. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems;Allgayer;J. Clin. Oncol.,2000

5. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns;Allgayer;Clin. Exp. Metastasis,1998

Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3